Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Principal Investigator
Madhukar Trivedi, MD
University of Texas Southwestern Medical Center

Co-Lead Investigator & Project Director
Robrina Walker, PhD
University of Texas Southwestern Medical Center

This double-blinded, placebo-controlled study will investigate the effectiveness and safety of a combination pharmacotherapy for adults with moderate to severe methamphetamine use disorder. A total of 370 treatment-seeking participants will be randomized to either the 1) Active Medication Condition and receive injections of extended release naltrexone (Vivitrol®) plus 450 mg of once-daily oral extended-release bupropion tablets or the 2) matching placebo arm and receive injections of placebo plus once-daily oral placebo tablets. Injections will be administered every 3 weeks. During this 12-week medication phase, participants may be re-randomized to another arm, as determined by the a priori adaptive aspect of the study design; participants appearing to respond well to their originally-assigned arm will not be re-randomized. The primary goal of the study is to evaluate the effectiveness of the active medication condition compared to the placebo arm. After the medication phase, participants will complete a medication taper and post-medication phase follow-up visits during weeks 13 and 16.



Publications about CTN-0068 (NCT03078075)

NIDA protocol page


Texas (Lead) search www
UCLA Center for Behavioral Addiction Medicine  
UT Health Center for Neurobehavioral Research on Addiction  
Greater New York search www
New York State Psychiatric Institute  
Northstar search www
Hennepin County Medical Center  
Southern Consortium search www
Behavioral Health Services of Pickens County  
Western States search www
CODA, Inc.  
San Francisco Department of Public Health Substance Use Research Unit  

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 6/2017 --